

# Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons

Hélène Doucet-Beaupré<sup>a,b</sup>, Catherine Gilbert<sup>a,b</sup>, Marcos Schaan Profes<sup>a,b</sup>, Audrey Chabrat<sup>a,b</sup>, Consiglia Pacelli<sup>c,d</sup>, Nicolas Giguère<sup>c,d</sup>, Véronique Rioux<sup>a,b</sup>, Julien Charest<sup>a,b</sup>, Qiaolin Deng<sup>e</sup>, Ariadna Laguna<sup>e,f</sup>, Johan Ericson<sup>e</sup>, Thomas Perlmann<sup>e,f</sup>, Siew-Lan Ang<sup>g</sup>, Francesca Cicchetti<sup>a,h</sup>, Martin Parent<sup>a,b</sup>, Louis-Eric Trudeau<sup>c,d</sup>, and Martin Lévesque<sup>a,b,1</sup>

<sup>a</sup>Department of Psychiatry and Neurosciences, Faculty of Medicine, Université Laval, Québec QC G1V 0A6, Canada; <sup>b</sup>Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec, Québec, QC G1J 2G3, Canada; <sup>c</sup>Department of Pharmacology, Central Nervous System Research Group, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; <sup>d</sup>Department of Neurosciences, Central Nervous System Research Group, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; <sup>e</sup>Department of Cell and Molecular Biology, Karolinska Institutet, 171 77 Stockholm, Sweden; <sup>f</sup>The Ludwig Institute for Cancer Research, 171 77 Stockholm, Sweden; <sup>g</sup>The Francis Crick Institute, London, NW1 2BE, United Kingdom; and <sup>h</sup>Centre de recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1V 4G2, Canada

Edited by Anders Bjorklund, Lund University, Lund, Sweden, and approved June 10, 2016 (received for review October 15, 2015)

**The LIM-homeodomain transcription factors Lmx1a and Lmx1b play critical roles during the development of midbrain dopaminergic progenitors, but their functions in the adult brain remain poorly understood. We show here that sustained expression of Lmx1a and Lmx1b is required for the survival of adult midbrain dopaminergic neurons. Strikingly, inactivation of Lmx1a and Lmx1b recreates cellular features observed in Parkinson's disease. We found that Lmx1a/b control the expression of key genes involved in mitochondrial functions, and their ablation results in impaired respiratory chain activity, increased oxidative stress, and mitochondrial DNA damage. Lmx1a/b deficiency caused axonal pathology characterized by  $\alpha$ -synuclein<sup>+</sup> inclusions, followed by a progressive loss of dopaminergic neurons. These results reveal the key role of these transcription factors beyond the early developmental stages and provide mechanistic links between mitochondrial dysfunctions,  $\alpha$ -synuclein aggregation, and the survival of dopaminergic neurons.**

transcription factors | Parkinson's disease | mitochondrial dysfunctions | protein aggregates | dopamine neurons

Midbrain dopaminergic (mDA) neurons control key functions in the mammalian brain, including voluntary movement, associative learning, and motivated behaviors. Dysfunctions of the dopaminergic (DA) system underlie a wide variety of neurological and psychiatric disorders. The progressive and rather selective degeneration of mDA neurons is one of the principal pathological features of Parkinson's disease (PD) (1). In PD, neuronal loss is accompanied by the appearance of  $\alpha$ -synuclein-enriched intraneuronal inclusions called "Lewy bodies" and "Lewy neurites." The etiologies of PD remain unsolved, but mitochondrial dysfunction emerges as a central mechanism in inherited, sporadic, and toxin-induced PD (2).

Specification of the subtype identities of mDA neurons begins during embryonic development. The combinatory activation of transcription factors (TFs) and their target genes allows the progenitors to mature progressively and terminally differentiate into postmitotic neuron subtypes. Tremendous efforts have been made to describe the complex spatiotemporal expression of TFs during mDA neuronal development (see refs. 3 and 4 for reviews). After mDA neuron maturation, a large number of developmentally expressed TFs remain active throughout adulthood. Our knowledge of the functional roles of these TFs in mature neurons remains rudimentary. Accumulating evidence shows that transcription factors including the nuclear receptor related 1 protein (Nurr1), En1, Pitx3, Otx2, and Foxa2, which are recognized for their role in the early development of mDA neurons, are also required for the maintenance of phenotypic neuronal identity in the adult (5).

The LIM homeodomain genes *Lmx1a/b* are early determinants of the fate of mDA progenitors (6), and their actions are

essential at each step of DA neuronal generation (7, 8). The murine *Lmx1a* and *Lmx1b* proteins are closely related and share an overall amino acid identity of 64%, with 100% identity in their homeodomain and 67% and 83% identity in each LIM domain (9). These neuronal lineage-specific transcription factors control the expression of multiple downstream genes and ultimately determine the morphological, physiological, and functional identity of mDA neurons. It is noteworthy that *Lmx1a* is part of a minimal transcription factor mixture, along with *Mash1* and *Nurr1*, which is able to generate DA neurons directly from mouse and human fibroblasts without the necessity of reverting to a progenitor-cell stage (10). *Lmx1a* and *Lmx1b* continue to be expressed in postmitotic precursors and differentiating mDA neurons, but their functional importance in postnatal life is still unknown. Because human *LMX1A/B* polymorphism has been associated with PD (11), it is imperative to explore the putative role of *Lmx1a* and *Lmx1b* genes in the maintenance of mDA neurons.

In the present study, two different targeting approaches based on the Cre-lox recombination system were used to investigate the function of *Lmx1a/b* in mature mDA neurons. Our work provides mechanistic insights into the physiological relevance of *Lmx1a/b* in

## Significance

**Degeneration of midbrain dopamine neurons is the main pathological hallmark of Parkinson's disease. Identifying transcriptional programs that maintain these neurons in the adult brain will help us understand their specific vulnerability. Here, we show that the survival of dopaminergic neurons requires the ongoing action of LIM-homeodomain transcription factors Lmx1a and Lmx1b. We discovered an Lmx1a/b-dependent pathway maintaining mitochondrial functions in midbrain dopaminergic neurons. Accordingly, ablation of Lmx1a/b results in impaired respiratory chain activity, increased oxidative stress, and mitochondrial DNA damage and causes Lewy neurite-like pathology. Importantly, deletion of Lmx1a/b links metabolic impairment,  $\alpha$ -synuclein inclusions, and progressive neuronal loss. Modulation of this pathway opens new strategies to slow down or prevent the death of vulnerable neurons in Parkinson's disease.**

Author contributions: H.D.-B. and M.L. designed research; H.D.-B., C.G., M.S.P., A.C., C.P., N.G., V.R., J.C., F.C., M.P., L.-E.T., and M.L. performed research; Q.D., A.L., J.E., T.P., S.-L.A., and M.L. contributed new reagents/analytic tools; H.D.-B., C.G., L.-E.T., and M.L. analyzed data; and H.D.-B., C.G., and M.L. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

<sup>1</sup>To whom correspondence should be addressed. Email: martin.levesque@fmed.ulaval.ca.


This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1520387113/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1520387113/-DCSupplemental).

the adult brain per se and also provides important cues concerning the mechanisms of neuronal degeneration processes. We found that *Lmx1a/b* are master regulator genes involved in the active maintenance of DA circuits throughout the lifespan. Our results uncover pathways downstream of *Lmx1a/b* that are involved in regulating the mitochondrial metabolism of mDA neurons. We discuss the relevance of our findings in the context of PD because the disruption of *Lmx1a/b* regulatory networks in a genetic mouse model recreates some of the cellular features of the disease to an unprecedented level of accuracy.


## Results

**Expression of *Lmx1a* and *Lmx1b* in the Postnatal Brain.** We used in situ hybridization and immunohistochemistry on wild-type mouse midbrain sections to investigate the expression profiles of *Lmx1a* and *Lmx1b* throughout the postnatal period (Fig. 1). The *Lmx1a* hybridization signal was highest at postnatal day 1 (P1) and diminished progressively with aging but still was present at 6 mo (P200) (Fig. 1A). The *Lmx1b* transcript level was higher at P7 than during the embryonic period and remained expressed at moderate levels throughout all postnatal stages from P1 to P200 (Fig. 1A). Triple-immunofluorescence staining in P200 midbrain sections revealed that nearly all mDA neurons were positive for *Lmx1a*, *Lmx1b*, and tyrosine hydroxylase (TH) (Fig. 1B). We confirmed the expression pattern by Western blotting analysis of ventral midbrain extracts. Although the level of expression is reduced in the adult brain as compared with the early postnatal stage, robust protein levels of both *Lmx1a* and *Lmx1b* (Fig. 1C and Fig. S1) were still detectable in aged (13-mo-old) mice, supporting previous reports (12–14).

**Conditional Deletion of *Lmx1a* and *Lmx1b* in Mature mDA Neurons Leads to Progressive DA Neuron Loss.** Because *Lmx1a* and *Lmx1b* can compensate for the loss of the other (8), we evaluated the involvement of both factors in the maintenance of mature mDA neurons using an *Lmx1a* and *Lmx1b* double conditional-knockout (cKO) mutant, *Lmx1a/b* cKO. To delete both alleles of these genes specifically in mDA neurons without affecting either the specification or the normal proliferation of DA progenitors, we generated a mouse line in which *Lmx1a* and *Lmx1b* are conditionally deleted in postmitotic mDA neurons



**Fig. 1.** *Lmx1a* and *Lmx1b* expression in mDA neurons is maintained into adulthood. (A) *Lmx1a* and *Lmx1b* transcripts levels were compared in P1, P7, P60, and P200 in C57BL6 mouse ventral midbrain cryosections using non-radioactive in situ hybridization. (Scale bar, 250  $\mu$ m.) (B) Stitched images of confocal tiles showing immunofluorescent staining with anti-*Lmx1a* (green), anti-*Lmx1b* (red), and anti-TH (blue) in ventral midbrain cryosections of P1 and P200 C57BL6 mouse midbrain illustrating the protein expression. (Scale bar, 250  $\mu$ m.) (C) Western blot and quantification of *Lmx1a* and *Lmx1b* expression in E15, P1, P7, P20, adult (3 mo old), and aged (9 mo old) mouse midbrain.  $n = 3$  animals per age. The molecular mass of the protein marker is indicated.



**Fig. 2.** Effects of *Lmx1a* and *Lmx1b* ablation on mDA neurons. (A–C) Immunohistological analyses of TH staining in the VTA and SNpc in the midbrains of P1 (A), P20 (B), and >P60 (C) *Lmx1a/b* cKO and control mice using DAB staining against TH. The arrows in C denote the DA neuronal loss. (Scale bar, 500  $\mu$ m.) (D and E) Quantification of DA neuronal loss in the VTA (D) and SNpc (E) by stereological count at P1, P20, P60, and P200; values are derived from at least four mice, three sections per brain. (F) Coexpression of DAT (green) and TH (red) in midbrain sections from 60-d-old *Lmx1a/b* cKO and control mice (stitched confocal images). Arrows indicate that the loss of TH<sup>+</sup> cells is correlated with a loss of the DAT signal. (Scale bar, 500  $\mu$ m.) (G)  $\beta$ -Gal staining (blue) on midbrain sections from 60-d-old *Lmx1a/b* cKO R26RLacZ<sup>+/+</sup> and control mice confirming the loss of DA neurons. The genotype of control mice in G is *DatCre<sup>+/+</sup>R26RLacZ<sup>+/+</sup>*. (Scale bar, 500  $\mu$ m.)

(Fig. S2). We crossed double-homozygous *Lmx1a* and *Lmx1b* floxed mice with heterozygous mice expressing Cre recombinase under control of the DA transporter (DAT) gene locus (*Dat-Cre*). In this line, Cre recombinase is expressed at embryonic day 13.5 (E13.5) in virtually all mDA neurons (15). Littermate *DAT<sup>+/+</sup>Lmx1a/b F<sup>+/+</sup>* or *F/F* mice were used as controls, unless noted otherwise in the text.

Unbiased stereological and immunohistological analyses of the ventral midbrain were conducted in *Lmx1a/b* cKO and control mice. Localization, distribution, and neuronal counts of TH<sup>+</sup> neurons in the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNpc) showed no observable differences between *Lmx1a/b* cKO and control mice at P1 (Fig. 2A, D, and E). At P20, stereological neuronal counts showed no differences in the number of TH<sup>+</sup> neurons in the VTA (Fig. 2B and D), but we measured a significant neuronal loss in the SNpc of *Lmx1a/b* cKO mice (Fig. 2B and E). In 2-mo-old (P60) *Lmx1a/b*-deficient mice, we measured a 35% reduction in the number of TH<sup>+</sup> neurons in the VTA and a 44% reduction in the SNpc (Fig. 2D and E). Accordingly, the density of DA dendrites that normally penetrate deep into the substantia nigra pars reticulata was greatly reduced in *Lmx1a/b* cKO mice (Fig. 2C). The number of TH<sup>+</sup> neurons in the VTA and SNpc did not decrease substantially between P60 and P200 (around 6.5 mo), because the percentage of reduction in both the VTA and SNpc remained similar in *Lmx1a/b* cKO and control mice.

To confirm the complete loss of TH neurons, stereological analysis for DAT- and Nissl-stained cells was conducted at P60. The loss of TH<sup>+</sup> neurons correlated with the loss of the DAT and Nissl signal (Fig. 2F and Fig. S3). We also used a *LacZ* reporter line to visualize neuronal loss. We crossed *Lmx1a/b* cKO mice with a *Rosa26 LacZ* reporter line (16). In these mice, *LacZ* is conditionally expressed in mDA neurons that have undergone Cre-mediated excision. The ventral midbrain of the *Dat-Cre* control mice was densely packed with cells expressing  $\beta$ -gal. By contrast, only sparse  $\beta$ -gal<sup>+</sup> neurons were scattered within the VTA and SNpc of *Lmx1a/b* cKO mice, confirming the loss of mDA neurons (Fig. 2G).

**Abnormal Accumulation of  $\alpha$ -Synuclein in mDA Nerve Terminals of *Lmx1a/b* cKO Mutant Mice.** In accordance with the difference in the number of TH<sup>+</sup> cell bodies in the SNpc at P20 (Fig. 2E), a reduction in TH immunoreactivity was observable in the striatum of *Lmx1a/b* cKO mutant mice (Fig. 3A and B). This result was further confirmed by Western blotting analysis of striatal




homogenates which revealed an ~50% decrease of TH and DOPA decarboxylase (DDC) protein levels (Fig. 3E and Fig. S4) at P20. The TH<sup>+</sup> nerve fibers in the striatum of mutant mice appeared dystrophic, and abnormal axon terminal enlargements were observed (Fig. S5 A and B). Dystrophic neurites were present as early as P20, and fiber pathology was aggravated with aging. The most striking finding in the striatum of *Lmx1a/b* cKO mice was the abundance of large TH<sup>+</sup> spheroid-like structures (Fig. 3B). Immunohistological staining from P20 and 2-mo-old mice showed numerous TH<sup>+</sup> puncta of various sizes (5–20  $\mu$ m), accumulating predominantly in dystrophic nerve fibers in the striatum. Double immunostaining experiments with antibodies directed against aggregation-prone proteins were performed to identify the composition of the puncta. Puncta were found to be  $\alpha$ -synuclein immunoreactive (Fig. 3 C and D) at P60.  $\alpha$ -Synuclein is a small presynaptic protein well known for its close association with PD pathology. Lewy bodies and Lewy neurites observed in PD are largely composed of abnormal fibrillar aggregates enriched with a phosphorylated form of  $\alpha$ -synuclein. Striatal tissue extracts were assayed by Western blotting to determine

whether phosphorylated  $\alpha$ -synuclein (phospho-Ser129  $\alpha$ -synuclein) was present. The ratio of phospho-Ser129  $\alpha$ -synuclein to total  $\alpha$ -synuclein from *Lmx1a/b* cKO mice aged 6 mo or older was increased significantly compared with controls (Fig. 3F and Fig. S4). In accordance with the abnormal DA nerve terminals found in the striatum, HPLC of striatal extracts confirmed the reduction of DA and DA metabolites in mutant animals (Fig. 3 G and H). Scattered TH<sup>+</sup> cell bodies were also found in the striatum of *Lmx1a/b* cKO mice, a compensatory mechanism previously reported in the striatum from PD brains (Fig. S5C) (17, 18).

Next, we analyzed the spontaneous locomotor activity of the *Lmx1a/b* cKO mutant mice in an open-field chamber at different ages. The *Lmx1a/b* cKO mice were hyperactive. The total distances traveled were significantly affected in mutant mice and also gave the clearest signal of a progressive decline in locomotor activity with aging (Fig. 3I).

**Degeneration of mDA Neurons Following Adeno-Associated Virus-Mediated Cre Inactivation of *Lmx1a/b* in Adult Mice.** To eliminate putative confounding effects of compensatory postnatal




**Fig. 3.** Abnormal nerve terminals in *Lmx1a/b* cKO mice. (A and B) The immunohistological striatal TH staining pattern was compared in P60 control (A) and *Lmx1a/b* cKO (B) mice. In B, the higher-magnification image shows dystrophic and abnormal axon terminal enlargements of TH<sup>+</sup> nerve fibers as well as large TH<sup>+</sup> spheroid-like structures. (Scale bar, 50  $\mu$ m.) See also Fig. S5. (C and D) Identification of the axonal spheroids using coimmunostaining of  $\alpha$ -synuclein (green) and TH (red) in the striatum of control (C) and *Lmx1a/b* cKO (D) mice. (Scale bar, 50  $\mu$ m.) (E and F) Western blotting analysis of TH, DDC, and phospho- $\alpha$ -synuclein levels in extracts from the striatum of P20 (E) and 6-mo-old (F) control and *Lmx1a/b* cKO mice ( $n = 3$  animals per genotype). Representative blots are shown in Fig. S4. (G and H) HPLC analysis of striatal content (DA, DOPAC, 3-MT, and HVA) in P20 (G) and 6-mo-old (H) control and *Lmx1a/b* cKO mice. Values are derived from at least three mice per group. (I) *Lmx1a/b* cKO mice and their controls were placed in the open-field chamber. Horizontal and vertical activities (measured by beam breaks) and the total distance traveled were measured for 10 min in P30, P60, P90, P200, and P300 mice.

developmental mechanisms, we deleted *Lmx1a/b* in mDA neurons using viral delivery of Cre recombinase through stereotaxic injection in the midbrain of adult mice (Fig. 4 *A* and *B* and Fig. S6). Mice that received unilateral intra-SNpc/VTA injections of a Cre virus recapitulated the essential neuropathological features observed in *Lmx1a/b* cKO mice (Fig. 4 *C*, *D*, *F*, and *G*). Stereological analysis of TH<sup>+</sup> cells showed no difference in neuronal count 2 mo after injection. However, a significant decrease was measured 4 mo and 6 mo after the injection of adeno-associated virus (AAV) Cre (Fig. 4*E*). Four months following stereotaxic infusion of the Cre virus, TH optical density was reduced throughout the striatum on the lesioned side of AAV Cre-injected animals (Fig. 4 *F–H*). Dystrophic swollen TH<sup>+</sup> neurites and large spheroid-like structures were also observed in the striatum on the lesioned side of the brain (Fig. 4 *I* and *J*). TH and  $\alpha$ -synuclein colocalized in these spheroids, in contrast to the diffused distribution seen in the striatum of the animals injected with control virus (Fig. 4 *I* and *J*). To verify the progression of the process, we also stained TH and  $\alpha$ -synuclein at an earlier time point (2 mo postinjection); at this stage, TH and  $\alpha$ -synuclein do not colocalize in these spheroids (Fig. S7*A*).  $\alpha$ -Synuclein undergoes several posttranslational modifications. For example, phosphorylation at serine 129 (pS129) has frequently been linked to PD pathogenesis because it may increase the formation of  $\alpha$ -synuclein aggregates. At the midbrain level, a difference in pS129 content and subcellular localization was observed between

control and AAV Cre-injected animals (Fig. 4 *K* and *L*). Additionally, AAV Cre-injected animals demonstrated a significant decrease in vertical activity (a decrease of nearly 75% compared with control mice) 4 mo following the virus injection (Fig. 4*M*). To evaluate the influence of the age of ablation on the degenerative process, we injected AAV Cre vector in young (20-d-old) and aged (20-mo-old) mice. Locomotor measurements indicate that young mice cope better with the loss of *Lmx1a/b*, because no motor dysfunction was observed in these mice 3 mo after Cre delivery. By contrast, aged mice showed significant motor impairment in horizontal activity, vertical activity, and total distance traveled only 1 mo after the AAV Cre injection (Fig. S8).

***Lmx1a/b* Coordinate the Expression of Mitochondrial-Associated Genes.** In an attempt to elucidate the mechanisms by which *Lmx1a* and *Lmx1b* participate in the postnatal maintenance of mDA neurons, we next investigated potential relevant target genes. We first used laser-capture microdissection (LCM) to isolate TH-stained neurons of the SNpc and VTA from *Lmx1a/b* mutant and control mice at E15.5 followed by next-generation RNA-sequencing (RNA-seq) to obtain the differentially expressed genes. We found 517 genes differently expressed by at least twofold between mutant and control mice. Gene Ontology (GO) analysis was performed to identify possible enrichment genes with specific biological themes. A spectrum of biological processes was



**Fig. 4.** Inactivation of *Lmx1a* and *Lmx1b* in mDA neurons by viral-vector delivery of Cre recombinase impairs the survival of adult midbrain DA neurons. (*A* and *B*) Schematics depicting the injection of control mutated Cre-encoding (AAV  $\Delta$ Cre-GFP) virus (*A*) or of Cre-encoding (AAV Cre-GFP) virus (*B*) in the ventral midbrain of *Lmx1a/b* F/F adult (2-mo-old) mice. (*C* and *D*) Stitched confocal images of TH and GFP staining from a representative section of *Lmx1a/b* F/F mice 6 mo after unilateral injection with either control or Cre-encoding (AAV Cre-GFP) virus. Infected cells are shown in green, and the arrow denotes the DA neuronal loss. (Scale bar, 500  $\mu$ m.) (*E*) Quantification of DA neuronal loss in the VTA and the SNpc by stereological counting of TH<sup>+</sup> cells at 2, 4, and 6 mo after the injection; values are derived from at least four mice, three sections per brain. (*F* and *G*) TH staining in the striatum (red) shows the DA axon distribution (stitched confocal images). The arrow indicates the DA axonal loss in the dorsolateral striatum on the injected side. (Scale bar, 1 mm.) (*H*) Densitometry quantification of TH immunostaining intensity in the striatum of mice infected with the control (mutated Cre) and Cre-GFP vectors ( $n = 3$ ). (*I* and *J*) Identification of the axonal spheroids using costaining of  $\alpha$ -synuclein (green) and TH (red) in the striatum of the side injected with either control or Cre-encoding AAV. (Scale bar, 50  $\mu$ m.) (*K* and *L*) Immunohistological analysis of phosphorylated  $\alpha$ -synuclein at S129 (blue) in TH<sup>+</sup> neurons (red) in the midbrain of injected mice. High levels of phospho  $\alpha$ -synuclein S129 were detected in the nucleus of TH<sup>+</sup> neurons in AAV Cre-GFP-injected animals compared with controls. (*M*) Behavioral characterization of *Lmx1a/b* F/F mice 6 mo after AAV infection in the SNpc. Open-field horizontal and vertical activity (measured by beam breaks) and total distance traveled were measured ( $n = 5$ ).


significantly enriched, including the mitotic cell-cycle checkpoint, regulation of the cell cycle, and protein–DNA complex assembly, as is consistent with the established roles for developmental transcription factors (Fig. 5B). GO classification also showed that overrepresentation of genes associated with mitochondrial processes such as the long-chain fatty acid metabolic process, acyl-CoA metabolic process, electron transport chain, protein folding, and organelle organization was repressed in mutant mice (Fig. 5B). By comparing the differentially expressed gene list with microarray analysis of *LMX1A*-overexpressing MN9D DA cells (19), we identified several putatively regulated genes known to be relevant in mitochondrial functions (Table S1). We also searched our RNA-seq list to find genes related to previously identified molecular interactors of *LMX1B* (20) and found candidate genes involved in stress protection. Next, we validated each candidate gene as an *Lmx1a/b* target by RT quantitative PCR (RT-qPCR)

from laser-microdissected mDA neurons from P1 control and *Lmx1a/b* cKO mice (Fig. 5A) (21).

mRNA levels of the mitochondrial complex I genes *Ndufa3*, *Ndufa2*, and *Ndufa4*, the mitochondrial complex III gene *Uqcrcq*, and the mitochondrial complex IV gene *Cox6a*, all of which are nuclear-encoded subunits of the respiratory chain, were significantly lower in LCM-dissected tissue from *Lmx1a/b* cKO mice (Fig. 5B). Although it has not been identified as a target of *Lmx1a/b*, we included the mitochondrial *Cox1* gene in our analysis as a mitochondrial DNA marker to verify whether the difference in the mRNA level observed in the respiratory chain subunits was associated with a change in mtDNA and/or mitochondrial quantity. No significant difference in the *Cox1* gene level was detected between control and *Lmx1a/b* cKO mice, suggesting the absence of a large change in mitochondrial number. Nuclear respiratory factor-1 (Nrf1), an essential transcription factor for the integration of nuclear- and mitochondrial-encoded gene transcription (22), was differentially expressed in control and mutant mDA tissue, with a highly significant decrease in *Lmx1a/b* cKO mice. These observations suggest that *Lmx1a/b* control the expression of both mitochondrial transcription factor (Nrf1) and nuclear-encoded mitochondrial genes. To confirm the correlation between *Lmx1a/b* deficiency and *Nrf1* down-regulation, we forced the expression of *Lmx1a* and *Lmx1b* in primary neuronal cultures through transient transfection. Three days after overexpression of *Lmx1a*, a three-fold increase in *Nrf1* expression was detected (Fig. 5C). Overexpression of *Lmx1b* also resulted in a reproducible and robust 15-fold up-regulation of *Nrf1* (Fig. 5D).

We also investigated the *Hspa8* gene, which encodes the heat shock cognate 70 (Hsc70) protein, the constitutively expressed form of Hsp70. Immunoprecipitation experiments identified Hsp70 as a likely interactor with *Lmx1b* (20). Hsc70 is a specific chaperone known to interact with the PD-associated protein  $\alpha$ -synuclein (23, 24). A significantly lower mRNA level of *Hspa8* was measured in *Lmx1a/b* cKO mice (Fig. 5C).

**Deficiency in *Lmx1a/b* Leads to Impaired Mitochondrial Respiration and DA Neuronal Degeneration in Vitro.** To determine whether the alteration in transcriptional regulation by *Lmx1a/b* had any functional consequence on mitochondrial bioenergetics, we next performed respirometry experiments on 10-d-old mDA neurons cultured from control and *Lmx1a/b* cKO mice. We assessed the respiration rate as measured by basal and maximal [uncoupled with carbonylcyanide-m-chlorophenylhydrazine (CCCP)] oxygen consumption rate (OCR, measured in picomoles of oxygen per minute) using a Seahorse extracellular flux analyzer. Cellular respiration was measured in live neurons to estimate mitochondrial oxidative phosphorylation. These experiments demonstrated that the basal OCR was significantly decreased in *Lmx1a/b* cKO neurons, as is consistent with the decreased mitochondrial respiration in these cells (Fig. 5E). This decrease in respiration could be attributable to a lower mitochondrial density or to a reduced oxidative capacity of mitochondria. Furthermore, the maximal respiratory capacity was significantly lower in neurons from *Lmx1a/b* cKO mice than in neurons from controls. The respiratory control ratio, i.e., the ratio of maximal to basal OCR, was significantly lower in neurons from *Lmx1a/b* cKO mice than in neurons from controls, indicating a lower spare mitochondrial capacity. These data suggest the involvement of a mitochondrial dysfunction at the respiratory chain level rather than a reduction in mitochondrial density. Together, these results indicate that in *Lmx1a/b* cKO mice the mDA neurons have less potential respiratory capacity to face increased energetic demands and/or various stresses. Likewise, the viability of *Lmx1a/b*-deficient neurons in primary DA neuronal cultures also revealed their higher vulnerability. After 10 d, a 25% reduction in mDA neuronal survival was measured in primary DA neuron cultures from *Lmx1a/b* cKO mice compared with controls (Fig. 5E).



**Fig. 5.** *Lmx1a/b* coordinate the expression of mitochondrial-associated genes. (A) Schema illustrating rapid TH immunostaining, LCM, and mRNA isolation. (Scale bars, 500  $\mu$ m.) (B) Enrichment of GO terms for biological processes associated with down-regulated genes in *Lmx1a/b* cKO. (C) RT-qPCR analysis showing *Nrf1*, *Ndufa2*, *Ndufa3*, *Ndufa4*, *Ndufv1*, *Uqcrcq*, *Cox1*, *Cox6a*, and *Hspa8* mRNA expression in the ventral midbrain of control and *Lmx1a/b* cKO mice at P1. (D) RT-qPCR analysis showing *Lmx1a*, *Lmx1b*, and *Nrf1* mRNA expression in mDA cultured neurons overexpressing *Lmx1a* (n = 5) and *Lmx1b* (n = 7). (E) Respirometry experiments in mDA cultured neurons from controls and *Lmx1a/b* cKO mice. CCCP, oxygen consumption rate in the presence of CCCP; OCR, oxygen consumption rate; RCR, respiratory control ratio. Mean basal OCR was 600 and 444  $\text{pM}\cdot\text{min}^{-1}\cdot 10^4$  neurons $^{-1}$  for control and *Lmx1a/b* cKO neurons, respectively, and the mean for uncoupled OCR was 976 and 601  $\text{pM}\cdot\text{min}^{-1}\cdot 10^4$  neurons $^{-1}$  for control and *Lmx1a/b* cKO neurons, respectively. The graph at the right compares the survival of DA neurons from control and *Lmx1a/b* cKO mice after 10 DIV (n = 5).




**Lmx1a/b Mutant Cells Exhibit Overproduction of Reactive Oxygen Species.** Defective function at the level of the mitochondrial electron transport chain could lead to excessive production of reactive oxygen species (ROS). Given the observed mitochondrial impairment in midbrain neurons of *Lmx1a/b* cKO mice, we next used primary neuronal cultures of the ventral midbrain from controls and *Lmx1a/b* cKO mice to examine ROS production. Dissociated P1 midbrain was cultured at low density, a condition under which mDA neurons undergo gradual cell death. A live-cell imaging technique using a redox-sensitive probe (CellROX) after 3 d of culture revealed a significantly higher rate of ROS production in *Lmx1a/b* cKO cells than in controls (Fig. 6 A–C and Fig. S9A). These results suggest that the *Lmx1a/b* mutant cells could generate increased ROS levels under stress conditions.

**Deficiency in *Lmx1a/b* Leads to mtDNA Damage.** Oxidative damage to mitochondrial DNA is observed in several age-associated disorders, including PD. Given the mitochondrial impairment and increased oxidative stress observed in midbrain neurons of *Lmx1a/b* cKO mice, we next evaluated damage to mtDNA. Abasic sites are a type of DNA damage, often arising from oxidative stress, in which loss of a purine or pyrimidine base occurs (25). Using an adapted histochemical assay (25), elevated levels of abasic sites were measured in mDA neurons of *Lmx1a/b* cKO mice (Fig. 6D). In mature (2-mo-old) *Lmx1a/b* cKO mice, more than 64% of DA neurons demonstrated a striking ARP (aldehyde-reactive probe) fluorescence signal. In control mice, the ARP signal was fainter or absent in the majority of DA neurons. The colocalization of the ARP signal with the mitochondrial marker Tom20 demonstrated that accumulated abasic sites were specific to mitochondrial DNA and not to nuclear DNA. Accelerated accumulation of somatic mtDNA mutations in mDA neurons could contribute to the neurodegeneration observed in *Lmx1a/b* cKO mice.

**Altered Autophagy in *Lmx1a/b* cKO Mice.** Evidence suggests the involvement of autophagy deregulation in PD, and a recent study reported that removal of *Lmx1b* in postnatal mDA neurons produced enlarged axon terminals associated with an alteration in autophagy (13). In 2-mo-old *Lmx1a/b* cKO mice, we measured and confirmed a significant change in LC3-II at the protein level (Fig. S10A and B). A decrease in the LC3-II signal may indicate either a decrease in autophagosomal synthesis or an increase in autophagosomal clearance. In either case, our results suggest a modified autophagic flux. However, according to the RNA sequencing data at E15.5 and qPCR results at P1, genes of the autophagy-lysosomal pathway do not appear to be modified in *Lmx1a/b* cKO mice (Fig. S10).

**Forced Expression of *Nrf1* Rescues Aberrant ROS Levels in Vitro and both Cellular and Locomotor Deficits in Vivo.** To establish a relationship between the absence of *Lmx1a/b* and mitochondrial dysfunction, we chose to restore (and increase) the expression of *Nrf1*. Through the transcriptional control of several mtDNA genes and nuclear genes (putatively including NDUFA2, NDUFA3, and NDUFA4), *Nrf1* holds a dominant position in the hierarchy of mitochondrial homeostasis. We first restored *Nrf1* expression in primary cultures from *Lmx1a/b* mutant and control cells through transient transfection. Forced expression of *Nrf1* in DA neuronal cultures rescued abnormal production of ROS in *Lmx1a/b* mutant cells (Fig. 6A and B). Furthermore, *Nrf1* overexpression significantly increased the overall survival of mDA neurons from both mutants and controls (Fig. 6C). These in vitro findings suggest that *Nrf1* overexpression might reduce ROS production. To investigate the role of *Nrf1* in the regulation of mDA neuron maintenance further, rescue experiments were performed in which Cre-mediated inactivation of *Lmx1a/b*



**Fig. 6.** Deficiency in *Lmx1a/b* leads to overproduction of ROS and impaired mitochondrial DNA, and forced expression of *Nrf1* has a rescue effect both in vitro and in vivo. (A) Primary neuronal cultures of ventral midbrain from P1 control or *Lmx1a/b* cKO mice transfected with either control empty vector or a vector expressing *Nrf1* (CMV-*Nrf1*). Redox-sensitive probes (CellROX; green) were used. (Scale bar, 200  $\mu$ m.) (B and C) Densitometry quantification [corrected total cell fluorescence (CTCF)] of the ROS-sensitive probe (B) and relative percentage of TH<sup>+</sup> neurons surviving (C) after 3 DIV in *Lmx1a/b* F/F primary neuronal cultures where control (CMV-empty) and a *Nrf1*-expressing vector (CMV-*Nrf1*) were transfected ( $n = 5$ ). (D) Representative images (stitched confocal images) of the SNpc from P60 control and *Lmx1a/b* cKO mice. Tissue was stained for TH (red) and a mitochondrial marker Tom20 (blue) and was probed with an ARP (green) ( $n = 3$ ). (Scale bar, 20  $\mu$ m.) (E) TH and GFP labeling from a representative section of *Lmx1a/b* F/F mice 2 mo after unilateral injection with either AAV Cre-GFP or AAV Cre-GFP-Ires-*Nrf1* (stitched confocal images). (Scale bar, 500  $\mu$ m.) (F) Higher-magnification images of the midbrain from injected mice show no obvious abnormalities in the cell morphology and TH<sup>+</sup> neuron distribution following injection of Cre-*Nrf1* vector, whereas abnormal and dystrophic neurons were discernible in Cre-injected mice 2 mo after injection. (Scale bar, 20  $\mu$ m.) (G) Stereological neuronal counting of TH immunoreactive neurons. Data are presented as the percent of mDA neurons in the injected side relative to the noninjected side 6 mo after injection ( $n = 4$ ). (H) DA axons appear normal in the striatum of mice injected with AAV Cre-GFP-Ires-*Nrf1*. There is no sign of axonal spheroids enriched in  $\alpha$ -synuclein 2 mo after injection. (Scale bar, 100  $\mu$ m.) (I) Immunohistological labeling of phosphorylated  $\alpha$ -synuclein at S129 (blue) and TH<sup>+</sup> neurons (red) in the midbrain of injected mice. (Scale bar, 20  $\mu$ m.) (J) Behavioral measurements of horizontal and vertical movements and total traveled distance using an open-field chamber 6 mo after injection.

was combined with the forced expression of *Nrf1*. We generated a bicistronic vector coexpressing the functional Cre and *Nrf1* (AAV Cre-GFP-Ires-*Nrf1*) and injected it unilaterally into the ventral midbrain of *Lmx1a/b* double-floxed mice (Fig. 6E and Fig. S6). No obvious abnormalities were detected in the cell morphology and TH<sup>+</sup> neuron distribution 2 mo following injection of the Cre-*Nrf1* vector, but abnormal and dystrophic neurons were already discernible in Cre-injected mice (Fig. 6F and Fig. S7).

Histological analysis confirmed that the forced expression of *Nrf1* rescued mDA neuronal loss (Fig. 6G). Neither dystrophic swollen TH<sup>+</sup> neurites nor large spheroid-like structures were observed in the striatum on the lesioned side of the brain (Fig. 6H). Moreover, 6 mo postinjection, the striatum of mice injected with AAV Cre-GFP-Ires-*Nrf1* showed only a few abnormal terminals and no obvious signs of puncta (Fig. S7B). Immunohistological analysis of phosphorylated  $\alpha$ -synuclein in TH<sup>+</sup> neurons in the midbrain revealed no obvious pattern of accumulation or aggregation (Fig. 6I) as seen following AAV Cre injection (Fig. 4L). Locomotor abnormalities caused by *Lmx1a/b* deficiencies were fully rescued by the forced expression of *Nrf1* 6 mo following injection (Fig. 6G and Fig. S7).

## Discussion

Here we show that maintenance of mDA neurons in adulthood is severely compromised in the absence of *Lmx1a/b*. This finding indicates critical roles for *Lmx1a/b* in the adult brain and also offers unique insights into active maintenance mechanisms and DA neuron degeneration.

Our results describe the functional consequences of *Lmx1a/b* ablation in mature mDA neurons. In the *Lmx1a/b* cKO (Dat-Cre) mice, signs of degeneration first appear at P20 in the SNpc concomitant with the appearance of abnormal swollen terminals (called “spheroid-like structures”) preceding mDA neuronal death. PD is characterized by the degeneration of the mDA neurons, largely those of the SNpc. We observed a progressive loss of mDA neurons and a depletion of DA in the striatum of these mice from the age of 3 wk to 2 mo. The axonal spheroid-like structures that consistently characterized neurons lacking *Lmx1a/b* in these mice around age 2 mo were found to be immunoreactive for  $\alpha$ -synuclein. A prominent pathological hallmark of PD is the presence of Lewy bodies, which are intraneuronal inclusions principally composed of fibrillized  $\alpha$ -synuclein (26). After 2 mo and up to 6 mo, no further substantial neuronal loss was observed. The locomotor activity of the *Lmx1a/b* cKO (Dat-Cre) mouse model is perturbed but is difficult to interpret because the mice are hyperactive. However, the total distance they traveled declined constantly with aging in measurements taken up to age 1 y. Because *Lmx1a/b* regulate several genes during development of postmitotic mDA neurons, it is possible that the hyperactive phenotype could come from a developmental defect. According to our mRNA sequencing data, *Slitrk* family members seem to be regulated by *Lmx1a/b*. Although the function of these genes in mDA neurons remains unknown, these proteins have been shown to affect neurite outgrowth (27) and are involved in the formation of regulation synapses (28). Human genetic studies also have linked rare mutations in *SLITRK* genes with obsessive-compulsive spectrum disorders and other neuropsychiatric disorders including attention deficit hyperactivity disorder (29). A change in the expression of genes important for the correct wiring or for the synaptogenesis of mDA neurons could indeed have diverse consequences on behavior (including hyperactivity), but further studies would be required to confirm this hypothesis. To help clarify the action of *Lmx1a/b* in the adult brain, we used unilateral injections of AAV vector to deliver Cre recombinase to adult mDA neurons. The progression and main features of the degenerative process observed in these mice are consistent with the Dat-Cre mice model but without any hyperactivity. However, observations of this model suggest that the appearance of spheroid-like structures in the striatum precedes mDA neuronal death. Axonal degeneration is an early feature of PD supported by postmortem studies, functional neuroimaging, and toxin-induced animal models (30). The sequence of pathological events we observed in *Lmx1a/b* cKO mice is consistent with the retrograde degeneration model. These data suggest that, as in the dying-back PD hypothesis (31), nigrostriatal degeneration is revealed first by perturbation of axon terminals of the striatum. Inactivation of *Lmx1a* and *Lmx1b* in mDA neurons by viral-vector

delivery also allowed the observation of a progressive, PD-like deterioration of motor function when *Lmx1a/b* were ablated at age 2 mo or 2 y. We first observed a reduction in vertical movements at 12 wk, and mice showed a continuous decline over the following months. Interestingly, the progression of the observed motor symptoms (i.e., vertical movements declining earlier and faster than the horizontal movements) followed a pattern similar to that reported in the MitoPark PD mice model (32, 33). This behavioral phenotype has been suggested to model the early occurrence of axial/postural instability in PD (32). According to the locomotor measurements, the age of *Lmx1a/b* ablation seems to be critical. We observed a drastic locomotor deficit when *Lmx1a/b* were inactivated in aged mice. By contrast, we could not detect significant changes in locomotor behavior in young mice 3 mo after *Lmx1a/b* inactivation.

Collectively, our results provide compelling evidence that *Lmx1a/b* cKO mice could serve as a model of PD, combining two major pathological features of the disease, i.e., Lewy neurite-like  $\alpha$ -synuclein accumulations and significant mDA neuron degeneration.

Dismantling the action of transcription factors that promote or repress the activity of thousands of genes is likely to have complex consequences, and the functional importance of *Lmx1a/b* is yet to be fully understood. Here, we provide evidence suggesting that *Lmx1a/b* can modulate mitochondrial metabolism. We propose that *Lmx1a/b* control key parts of the program that drives the generation and maintenance of DA neurons. This program includes not only the essential components belonging to the DA pathway but also the unique mitochondrial features of mDA neurons and most likely the constitutive protection required for their survival (34). Therefore, *Lmx1a/b* might be a key player in the cross-talk between genetic and metabolic signaling that occurs during development, a capacity that persists in mature mDA neurons.

Among the mitochondrial impairments contributing to the etiology of PD, complex I deficit seems to be the principal contributor (35). Mitochondrial complex I (NADH ubiquinone oxidoreductase) is the first and largest complex of the respiratory chain. Key genes coding for mitochondrial complex I (i.e., *Ndufa2*, *Ndufa3*, and *Ndufa4*) are down-regulated in *Lmx1a/b* cKO mice. *NDUFA3* has recently been found necessary for the formation of a functional holoenzyme (36). *NDUFA2* and *NDUFA4* mutations have been linked to Leigh disease, a severe neurological disorder. *NDUFA2*, *NDUFA3*, *NDUFA4*, *UQCRCQ*, and *COX6A* have all been identified in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway map representing the causative gene and molecular network in PD ([www.genome.jp/kegg/](http://www.genome.jp/kegg/)).

The observation that key genes coding for electron transport complex I and complex III proteins are specifically down-regulated in *Lmx1a/b* cKO mice supports the hypothesis of a link between these TFs and mitochondrial metabolism. We also found a down-regulation of *Nrf1* in *Lmx1a/b* cKO mice. *Nrf1* occupies an upstream position in the hierarchy of transcription factors coordinating mitochondrial biogenesis and function. *Nrf1*, in collaboration with PGC-1 $\alpha$ , controls oxidative phosphorylation through the expression of many key nuclear-encoded mitochondrial genes, including all cytochrome *c* oxidase nuclear-encoded subunit genes (37, 38). Interestingly, several PD-related genes such as *PARK2* (Parkin), *PARK6* (Pink1), *PARK7* (DJ-1), and *PAELR* (GPR37) have been identified as *NRF1* targets (39). These data indicate that *Lmx1a/b* activity could influence mitochondrial functions, either directly or indirectly through *Nrf1* (or other transcriptional cascades). Consistent with these observations, our oxygen consumption measurements in neurons from *Lmx1a/b* cKO mice argue for the existence of a mitochondrial dysfunction at the level of the electron transport chain. Our results also suggest that *Lmx1a/b* cKO mitochondria operate with lower reserve capacity and thus might not cope effectively with periods of high bioenergetic demand. When overwhelmed, the mitochondrial







**Western Blot.** Ventral midbrain or striatal lysates prepared in radio-immunoprecipitation assay (RIPA) buffer were separated by SDS/PAGE and transferred onto nitrocellulose membranes (Bio-Rad). TH, DDC, Lmx-1a, Lmx1b,  $\alpha$ -synuclein, phospho- $\alpha$ -synuclein, and LC3 levels were assessed by Western blot analysis.

**Rapid TH Immunostaining and LCM.** A combination of rapid TH immunohistochemistry and LCM was performed using P1 mice (21). A model AS-LMD LCM system (Leica Microsystems) was used to outline and capture the region of the sections with TH-immunoreactive neurons. RNA from microdissected tissue was isolated using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems) according to the manufacturer's protocol.

**RNA Sequencing.** RNA was extracted using the PicoPure RNA Isolation Kit (Arcturus Engineering). The RNA-seq library was prepared using the Ovation RNA-Seq system (NuGEN). RNA-seq libraries were sequenced on an Illumina GAIIx, and analysis was performed using CLC Genomics Workbench version 1 (CLC bio). Expressed genes with an RPKM (reads per kilobase of transcript per million reads mapped) of 1 and above were described. Genes were described as differentially expressed when the expression difference of Lmx1a/b mutant tissue over control tissue was twofold or more. GO analysis was performed using the GOToolBox ([genome.crg.es/GOToolBox](http://genome.crg.es/GOToolBox)), using the MGI identities of the list of genes. Gene lists and GO term results are provided in *SI Materials and Methods*.

**RT-qPCR.** Real-time RT-qPCR analysis was performed using a LightCycler 480 (Roche Diagnostics) and analyzed with the LCS 480 software (version 1.5.0.39; Roche Applied Science). RNA samples obtained by LCM were reverse-transcribed into cDNA using the SuperScript III reverse transcriptase kit (Invitrogen). Relative quantifications were calculated using the  $\Delta\Delta CT$  formula and normalizing the target gene amount over at least two or three reference genes (*GAPDH*, *TBP*, and *RPL13*). Data are presented as the mean  $\pm$  SEM of the fold change relative to the expression at P1 and normalized against reference genes.

**Stereotaxic Injection of Recombinant AAV.** AAV vectors expressing functional Cre-recombinase and nonfunctional Cre-recombinase (used as a control), both fused to GFP, were produced as described previously (52). See *SI Materials and Methods* for AAV vector generation. For stereotaxic injections, 2-mo-old *Lmx1a<sup>F/F</sup>*; *Lmx1b<sup>F/F</sup>* mice ( $n = 7$ ) were used. To evaluate the effect of the age of ablation, 20-d-old and 20-mo-old *Lmx1a<sup>F/F</sup>*; *Lmx1b<sup>F/F</sup>* mice ( $n = 5$ ) were used also. Mice were anesthetized with isoflurane, and skulls were immobilized in a stereotaxic apparatus. A 0.5- $\mu$ L volume of virus [AAV Cre-GFP: 4.9 e10 genome copy (GC)/mL and AAV  $\Delta$ Cre-GFP: 8.6 e10 GC/mL] was injected unilaterally into the SNpc/VTA (anteroposterior:  $-3.5$  mm from bregma; mediolateral: 1.0 mm; dorsoventral: 4.0 mm). Animals were perfused 2, 4, or 6 mo after injection.

For the in vivo rescue experiment, 2-mo-old *Lmx1a<sup>F/F</sup>*; *Lmx1b<sup>F/F</sup>* mice were injected with a bicistronic vector coexpressing the functional Cre and Nrf1 (AAV Cre-GFP-Ires-Nrf1: 1.3 e12 GC/mL). Behavioral measurements were done at 2 and 6 mo after the injection. After behavioral measurements were performed, animals were perfused, and stereological analyses were done.

In addition to in situ hybridization (described above),  $\beta$ -gal staining and qualitative RT-PCR were used to confirm the efficiency of the viral vector (*SI Materials and Methods* and Fig. S6).

**Locomotor Activity.** The locomotor activity of AAV-injected mice was tested 4 and 6 mo postinjection in locomotor detection chambers (AccuScan Instruments, Inc.) equipped with 16 light beams located in both the horizontal and vertical planes. The activity was monitored using the activity-monitoring VersaMax version 3.0 software (AccuScan Instruments, Inc.). Mice were allowed to habituate to the chamber for 15 min and were tested over a 60-min period in the open field. Activity was measured by recording horizontal and vertical activity and was quantified as the number of beam breaks per minute. Total distance traveled by an animal during 10 or 60 min was also measured as a locomotor activity parameter.

**Detection of Mitochondrial DNA Damage.** The histochemical assay for the detection of abasic sites in the substantia nigra sections from 2-mo-old mice was performed as described previously (25). In brief, midbrain sections containing the SNpc and VTA were incubated with the ARP for 1 h, rinsed, and then immunostained for TH and the mitochondrial marker Tom20.

**Culture of Primary DA Neurons, Transient Transfection, and ROS Assay.** Primary DA neuronal cultures were prepared from the mesencephalon of P1 mice. See *SI Materials and Methods* for the culture of primary DA neurons and details of transient transfection. In brief, after 1 d in vitro (DIV), cultures were transfected using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. After 3 DIV, transfected cells were either used for RNA extraction using an RNeasy Mini kit (Qiagen) and processed further for RT-qPCR (see above) or fixed and immunostained for TH. For the ROS assay, cultures were transfected with CMV-Nrf1 (Dharmacon) or (CMV-empty). ROS quantification was performed by epifluorescence microscopy using CellROX (Invitrogen) according to the manufacturer's instructions on 3-d-old cultures (*SI Materials and Methods*). All images were captured with a Nikon Eclipse TE2000-U microscope and processed using MetaMorph, ImageJ, and Adobe Photoshop CS4.

**Statistical Analysis.** All statistical analyses were performed with GraphPad Prism software 4.0 (GraphPad Software, Inc.). Data are expressed as mean  $\pm$  SEM. The statistical significance of differences between two groups was calculated using Student's *t* test (with Welch's correction if the variance between the groups was different). Multiple groups of data were compared using ANOVA followed by the multiple comparisons test. Differences were considered significant at  $*P < 0.05$ ;  $**P < 0.001$ ;  $***P < 0.0001$ .

**ACKNOWLEDGMENTS.** We thank Drs. Armen Saghatelian, Simon Stott, and Emmanouil Matzakopoulou for useful comments and suggestions; Dr. Carmen Birchemier for sharing Lmx1b antibody; Richard D. Palmer for Cre-GFP and  $\Delta$ Cre-GFP plasmids; and the Plateforme d'Outils Moléculaire (<https://neurophotonic.ca/fr/pom>) for the production of viral vectors. This work was funded by Canadian Institutes of Health Research Grants MOP 311120 (to M.L.) and MOP106556 (to L.-E.T.) and by Natural Sciences and Engineering Research Council of Canada Grant 418391-2012 (to M.L.). H.D.-B. received a fellowship from the Fonds du Québec en Recherche, Santé (FRQS) and Fonds Québécois de Recherche sur le Parkinson. M.L. received salary support from the FRQS. N.G. and C.P. receive salary support from Parkinson Society Canada.

- Shulman JM, De Jager PL, Feany MB (2011) Parkinson's disease: Genetics and pathogenesis. *Annu Rev Pathol* 6(1):193–222.
- Abou-Sleiman PM, Muqit MM, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. *Nat Rev Neurosci* 7(3):207–219.
- Blaess S, Ang SL (2015) Genetic control of midbrain dopaminergic neuron development. *Wiley Interdiscip Rev Dev Biol* 4(2):113–134.
- Hegarty SV, Sullivan AM, O'Keefe GW (2013) Midbrain dopaminergic neurons: A review of the molecular circuitry that regulates their development. *Dev Biol* 379(2):123–138.
- Doucet-Beaupré H, Lévesque M (2013) The role of developmental transcription factors in adult midbrain dopaminergic neurons. *OA Neurosciences* 1(1):3.
- Smidt MP, et al. (2000) A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. *Nat Neurosci* 3(4):337–341.
- Deng Q, et al. (2011) Specific and integrated roles of Lmx1a, Lmx1b and Phox2a in ventral midbrain development. *Development* 138(16):3399–3408.
- Yan CH, Levesque M, Claxton S, Johnson RL, Ang SL (2011) Lmx1a and Lmx1b function cooperatively to regulate proliferation, specification, and differentiation of midbrain dopaminergic progenitors. *J Neurosci* 31(35):12413–12425.
- Robert O, Westphal H (2000) Functions of LIM-homeobox genes. *Trends Genet* 16(2):75–83.
- Caiazzo M, et al. (2011) Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature* 476(7359):224–227.
- Bergman O, et al. (2009) Do polymorphisms in transcription factors LMX1A and LMX1B influence the risk for Parkinson's disease? *J Neural Transm (Vienna)* 116(3):333–338.
- Dai JX, Hu ZL, Shi M, Guo C, Ding YQ (2008) Postnatal ontogeny of the transcription factor Lmx1b in the mouse central nervous system. *J Comp Neurol* 509(4):341–355.
- Laguna A, et al. (2015) Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease. *Nat Neurosci* 18(6):826–835.
- Zou HL, et al. (2009) Expression of the LIM-homeodomain gene Lmx1a in the postnatal mouse central nervous system. *Brain Res Bull* 78(6):306–312.
- Zhuang X, Masson J, Gingrich JA, Rayport S, Hen R (2005) Targeted gene expression in dopamine and serotonin neurons of the mouse brain. *J Neurosci Methods* 143(1):27–32.
- Srinivas S, et al. (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev Biol* 1(1):4.
- Huot P, et al. (2008) L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. *J Chem Neuroanat* 35(1):77–84.
- Porritt MJ, et al. (2000) New dopaminergic neurons in Parkinson's disease striatum. *Lancet* 356(9223):44–45.
- Hoekstra EJ, et al. (2013) Lmx1a is an activator of Rgs4 and Grb10 and is responsible for the correct specification of rostral and medial mdDA neurons. *Eur J Neurosci* 37(1):23–32.
- Hoekstra EJ, Mesman S, de Munick WA, Smidt MP (2013) LMX1B is part of a transcriptional complex with P5PC1 and PSF. *PLoS One* 8(1):e53122.

21. Chabrat A, Doucet-Beaupré H, Lévesque M (2015) RNA isolation from cell specific subpopulations using laser-capture microdissection combined with rapid immunolabeling. *Journal of Visualized Experiments* 98:e52510.
22. Evans MJ, Scarpulla RC (1989) Interaction of nuclear factors with multiple sites in the somatic cytochrome c promoter. Characterization of upstream NRF-1, ATF, and intron Sp1 recognition sequences. *J Biol Chem* 264(24):14361–14368.
23. Pemberton S, et al. (2011) Hsc70 protein interaction with soluble and fibrillar alpha-synuclein. *J Biol Chem* 286(40):34690–34699.
24. Pemberton S, Melki R (2012) The interaction of Hsc70 protein with fibrillar  $\alpha$ -Synuclein and its therapeutic potential in Parkinson's disease. *Commun Integr Biol* 5(1):94–95.
25. Sanders LH, et al. (2014) Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson's disease. *Neurobiol Dis* 70(0):214–223.
26. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. *Nat Rev Neurol* 9(1):13–24.
27. Aruga J, Mikoshiba K (2003) Identification and characterization of Slitrk, a novel neuronal transmembrane protein family controlling neurite outgrowth. *Mol Cell Neurosci* 24(1):117–129.
28. Yim YS, et al. (2013) Slitrks control excitatory and inhibitory synapse formation with LAR receptor protein tyrosine phosphatases. *Proc Natl Acad Sci USA* 110(10):4057–4062.
29. Proenca CC, Gao KP, Shmelkov SV, Rafii S, Lee FS (2011) Slitrks as emerging candidate genes involved in neuropsychiatric disorders. *Trends Neurosci* 34(3):143–153.
30. Burke RE, O'Malley K (2013) Axon degeneration in Parkinson's disease. *Exp Neurol* 246(0):72–83.
31. Chu Y, et al. (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. *Brain* 135(Pt 7):2058–2073.
32. Galter D, et al. (2010) MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. *Genes Brain Behav* 9(2):173–181.
33. Li X, et al. (2013) Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease. *PLoS One* 8(8):e71341.
34. Pacelli C, et al. (2015) Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. *Curr Biol* 25(18):2349–2360.
35. Greenamyre JT, Sherer TB, Betarbet R, Panov AV (2001) Complex I and Parkinson's disease. *IUBMB Life* 52(3-5):135–141.
36. Rak M, Rustin P (2014) Supernumerary subunits NDUFA3, NDUFA5 and NDUFA12 are required for the formation of the extramembrane arm of human mitochondrial complex I. *FEBS Lett* 588(9):1832–1838.
37. Dhar SS, Ongwijitwat S, Wong-Riley MTT (2008) Nuclear respiratory factor 1 regulates all ten nuclear-encoded subunits of cytochrome c oxidase in neurons. *J Biol Chem* 283(6):3120–3129.
38. Wong-Riley MT (2012) Bigenomic regulation of cytochrome c oxidase in neurons and the tight coupling between neuronal activity and energy metabolism. *Adv Exp Med Biol* 748:283–304.
39. Satoh J, Kawana N, Yamamoto Y (2013) Pathway analysis of ChIP-Seq-based NRF1 target genes suggests a logical hypothesis of their involvement in the pathogenesis of neurodegenerative diseases. *Gene Regul Syst Bio* 7:139–152.
40. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. *Cell* 120(4):483–495.
41. Kraysberg Y, et al. (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. *Nat Genet* 38(5):518–520.
42. Galluzzi L, Pietrocola F, Levine B, Kroemer G (2014) Metabolic control of autophagy. *Cell* 159(6):1263–1276.
43. Exner N, Lutz AK, Haass C, Winklhofer KF (2012) Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. *EMBO J* 31(14):3038–3062.
44. Zhao Z-Q, et al. (2006) Lmx1b is required for maintenance of central serotonergic neurons and mice lacking central serotonergic system exhibit normal locomotor activity. *J Neurosci* 26(49):12781–12788.
45. Exner N, Lutz AK, Haass C, Winklhofer KF (2012) Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. *EMBO J* 31(14):3038–3062.
46. Ma J, Shaw VE, Mitrofanis J (2009) Does melatonin help save dopaminergic cells in MPTP-treated mice? *Parkinsonism Relat Disord* 15(4):307–314.
47. Peoples C, et al. (2012) Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease. *Parkinsonism Relat Disord* 18(5):469–476.
48. Wallace BA, et al. (2007) Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. *Brain* 130(Pt 8):2129–2145.
49. Krawchuk D, Kania A (2008) Identification of genes controlled by LMX1B in the developing mouse limb bud. *Dev Dyn* 237(4):1183–1192.
50. Bousquet M, et al. (2011) Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease. *J Lipid Res* 52(2):263–271.
51. Fasano C, Thibault D, Trudeau LE (2008) Culture of postnatal mesencephalic dopamine neurons on an astrocyte monolayer. *Curr Protoc Neurosci* Chapter 3:Unit 3 21.
52. Zweifel LS, Argilli E, Bonci A, Palmiter RD (2008) Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors. *Neuron* 59(3):486–496.
53. Rozen S, Skaletsky H (1999) Primer3 on the WWW for general users and for biologist programmers. *Bioinformatics Methods and Protocols, Methods in Molecular Biology*, eds Misener S, Krawetz S (Humana Press, New York), Vol 132, pp 365–386.
54. McCloy RA, et al. (2014) Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. *Cell Cycle* 13(9):1400–1412.